different crypto currency, Related searches

So will heavyweights and large-cap stocks exert their strength? Looking at the trend of SSE 50, it is still very possible, because at present, the monthly trend of SSE 50 index is intact, and the index remains above the offensive line and above the long-term trend line. At present, it has the foundation to start a big market. Looking back, the index must remain above the monthly offensive line in all big markets, so this is a prerequisite. Since it is also available now, we can certainly expect something.At present, there is nothing wrong with the medium and long-term trend, so don't worry too much. Strategically, we will continue to watch more. Tactically, we will follow the trend and take the initiative step by step.The latest progress of stamp duty in Hong Kong has come!

The previous wave of adjustment of the Hang Seng Index was to step back on the long-term trend line at the daily level, which gained support and rebounded recently. Today, it closed above the offensive line, and the long-term trend at the daily level remains intact. On the monthly level, it fell below the offensive line last month, but it is above the offensive line at present, and it closed above 19,738 points this month. The problem is not big, and the long-term trend remains intact, and there is a basis for further strength.The latest progress of stamp duty in Hong Kong has come!Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.

There will be no surprises on Thursday!Dizhe Pharmaceutical announced that the company's private placement plan has been approved by the Shanghai Stock Exchange. This is the first time that the refinancing of the unprofitable enterprise on the Shanghai Stock Exchange has been approved since the release of "Keba Article".Dezhe Medicine is a listed company in science and technology innovation board, and it is an innovation-driven biomedical company with global competitiveness. Therefore, its refinancing has been approved by the Shanghai Stock Exchange, which also shows that the supervision is tolerant of companies with core technology and hard power. Although it may not be ideal financially for the time being, it has broad prospects and great imagination, which is worthy of support.